Insights into Nimbolide molecular crosstalk and its anticancer properties

• Published in: Medical oncology (Northwood, London, England) London, England), 2024-05, Vol.41 (6), p.158, Article 158
• Main Authors: Shaheen, Shabnum, Khalid, Sana, Aaliya, Khadija, Gul, Ambreen, Hafeez, Amna, Armaghan, Muhammad, Almarhoon, Zainab M., Calina, Daniela, Khan, Khushbukhat, Sharifi-Rad, Javad
• Format: Article
• Language: English
• Subjects: Angiogenesis; Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Antineoplastic Agents, Phytogenic - pharmacology; Antineoplastic Agents, Phytogenic - therapeutic use; Apoptosis - drug effects; Azadirachta - chemistry; Cancer; Cell Proliferation - drug effects; Hematology; Humans; Internal Medicine; Limonins - pharmacology; Limonins - therapeutic use; Medicine; Medicine & Public Health; Metastasis; Neoplasms - drug therapy; Neoplasms - metabolism; Neoplasms - pathology; Oncology; Pathology; Pharmacokinetics; Review Article; Signal Transduction - drug effects
• ISSN: 1559-131X; 1357-0560; 1559-131X
• DOI: 10.1007/s12032-024-02379-5

Nimbolide, one of the main ingredients constituent of Azadirachta indica (neem) leaf extract, has garnered attention for its potential as an anticancer agent. Its efficacy against various cancers and chemopreventive action has been demonstrated through numerous in vivo and in vitro studies. This updated review aims to comprehensively explore the chemopreventive and anticancer properties of nimbolide, emphasizing its molecular mechanisms of action and potential therapeutic applications in oncology. The review synthesizes evidence from various studies that examine nimbolide’s roles in apoptosis induction, anti-proliferation, cell death, metastasis inhibition, angiogenesis suppression, and modulation of carcinogen-metabolizing enzymes. Nimbolide exhibits multifaceted anticancer activities, including the modulation of multiple cell signaling pathways related to inflammation, invasion, survival, growth, metastasis, and angiogenesis. However, its pharmacological development is still in the early stages, mainly due to limited pharmacokinetic and comprehensive long-term toxicological studies. Nimbolide shows promising anticancer and chemopreventive properties, but there is need for systematic preclinical pharmacokinetic and toxicological research. Such studies are essential for establishing safe dosage ranges for first-in-human clinical trials and further advancing nimbolide's development as a therapeutic agent against various cancers. The review highlights the potential of nimbolide in cancer treatment and underscores the importance of rigorous preclinical evaluation to realize its full therapeutic potential.